Cephalon Discusses Treanda Study Results

Treatment-naive patients with chronic lymphocytic leukemia (CLL) who received Cephalon’s Treanda in a Phase III trial had better clinical outcomes compared with patients treated with chlorambucil.

The randomized, international, multicenter, open-label trial evaluated the safety and efficacy of bendamustine compared with chlorambucil in previously untreated patients with B-Cell CLL.

Overall response rate was higher with Treanda (bendamustine HCl) than with chlorambucil (68 percent versus 39 percent). Treanda also improved progression-free survival more than chlorambucil (21.7 months versus 9.3 months), according to Cephalon.